A Phase 1/ 2 Study of BAY 1895344 (elimusertib, IND#152153, NSC#810486) in Pediatric Patients with Relapsed or Refractory Solid Tumors
BAY 1895344 (elimusertib) is experimental because it has not been proven to work in a situation like yours. We are using BAY 1895344 (elimusertib) because it seems to work against cancer in test tubes and animals. BAY 1895344 (elimusertib) has been used in adults, but there is a lot that we do not know about BAY 1895344 (elimusertib) yet in children. This is a Phase 1/2 study because because the goal is to find the highest dose of BAY 1895344 (elimusertib) that we can give safely. We are testing new experimental drugs such as BAY 1895344 (elimusertib) in the hopes of finding a treatment that may be effective against cancer that has come back or that has not responded to standard therapy. This study looks at how well BAY 1895344 (elimusertib) works when given to children and young adults with refractory or recurrent solid tumors and lymphomas which contain specific genetic changes.More
Child to Adult
Age: Patients between ≥ 12 months and < 18 years of age. All patients for both Parts A and B must have a minimum BSA > 0.74 m2 All patients for both Parts A and B must have the ability to swallow BAY 1895344 (elimusertib) tablets intact.
Please visit with your provider regarding all eligibility requirements.
Childrens Hospital Colorado
Margaret Macy, MD
Protocol Number: 21-5013
More information available at ClinicalTrials.gov: NCT05071209
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers